-
The incidence of venous thromboembolism after curative colon cancer surgery within an enhanced recovery after surgery programme Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 Niklas Nygaard Baastrup, Astrid Kerstine Buch, Anders Kierkegaard Gundestrup, Anna Sofie Friis Olsen, Jakob Kleif, Issam Al-Najami, Ulrik Deding, Claus Anders Bertelsen, COMES II Copenhagen cOmplete Mesocolic Excision Study II study group, the Danish Colorectal Cancer Group
Based on three randomised controlled trials performed more than a decade ago, several national guidelines recommend prolonged venous thromboprophylaxis for 28 days following elective surgery for colon cancer. None of these studies were conducted within enhanced recovery after surgery setting. Newer studies indicate that prolonged prophylaxis might not be necessary with enhanced recovery after surgery
-
Does morphine attenuate the Inhibition of Platelet Aggregation for both oral and parenteral P2Y12 inhibitors? Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 Antonio Landi, Giuseppe Gargiulo, Giovanni Esposito, Gianluca Campo, Simone Biscaglia, Dik Heg, Marco Valgimigli
-
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 H. Lévesque, J.F. Viallard, E. Houivet, B. Bonnotte, S. Voisin, V. Le Cam-Duchez, F. Maillot, M. Lambert, E. Liozon, B. Hervier, O. Fain, B. Guillet, J. Schmidt, L.E. Luca, M. Ebbo, N. Ferreira-Maldent, A. Babuty, L. Sailler, P. Duffau, V. Barbay, S. Audia, J. Benichou, J. Graveleau, Y. Benhamou, CREHA Study investigators on behalf the scientific committee of the “Société Nationale Française de Médecine
Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a high mortality risk. Treatments aim to control bleeding and eradicate antibodies by immunosuppression. International recommendations rely on registers and international expert panels. CREHA, an open-label randomized trial, compared the efficacy and safety of cyclophosphamide and rituximab in
-
Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban Thromb. Res. (IF 7.5) Pub Date : 2024-03-15 Cindy Pereira Portela, Guido Stirnimann, Dino Kröll, Alessandro Aliotta, Lucas Veuthey, Maxime G. Zermatten, Lorenzo Alberio, Debora Bertaggia Calderara
-
Prognostic gene landscapes and therapeutic insights in sepsis-induced coagulopathy Thromb. Res. (IF 7.5) Pub Date : 2024-03-12 Xiaoli Ran, Jun Zhang, Yinyu Wu, Yunxia Du, Daiqin Bao, Haoyu Pei, Yue Zhang, Xiaoqiong Zhou, Rui Li, Xu Tang, Han She, Qingxiang Mao
Sepsis is a common and critical condition encountered in clinical practice that can lead to multi-organ dysfunction. Sepsis-induced coagulopathy (SIC) significantly affects patient outcomes. However, the precise mechanisms remain unclear, making the identification of effective prognostic and therapeutic targets imperative. The analysis of transcriptome data from the whole blood of sepsis patients,
-
The role of coagulation factors VIII, IX and XI in the prediction and mediation of recurrent thrombotic events in children with non-central venous catheter deep vein thrombosis Thromb. Res. (IF 7.5) Pub Date : 2024-03-07 Alessandra Bosch, Kirsten Brunsvig Jarvis, Leonardo R. Brandão, Yushu Zhou, Jennifer Vincelli, Nour Amiri, Laura Avila
The role of elevated coagulation factors VIII (FVIII), FIX, FXI for the prediction of recurrent thrombotic events in children after an index non-central venous catheter (non-CVC) related deep vein thrombosis (DVT) remains unclear. This study investigates the predictive role of FVIII, FIX, and FXI for recurrent thrombosis in children with index non-CVC DVTs, and the mediation effect of FVIII on chronic
-
Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure? Thromb. Res. (IF 7.5) Pub Date : 2024-03-07 Julie Vassart, Marie Didembourg, Laure Morimont, Clotilde Brisbois, Laurent Jamart, Aurélien Lebreton, François Mullier, Nathalie Donis, Julien Favresse, Jean-Michel Dogné, Jonathan Douxfils
-
Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-03-06 Joon Young Hur, Nayeon Choi, Jung Hye Choi, Jiyeong Kim, Young-Woong Won
There are few large-scale, population-based studies detailing the risks of thrombosis, hemorrhage, leukemic transformation in patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF). We performed a nationwide longitudinal cohort study using the Korean National Health Insurance System (NHIS) database. MPN patients
-
Acute and subacute effects of strenuous exercise on platelet aggregation, coagulation and fibrinolysis in patients with stable coronary artery disease Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Jacobina Kristiansen, Erik L. Grove, Tórur Sjúrðarson, Magni Mohr, Steen D. Kristensen, Anne-Mette Hvas
Strenuous exercise may occasionally cause coronary thrombosis with myocardial infarction and sudden cardiac death. Patients with stable coronary artery disease (CAD) ( = 164) and healthy individuals ( = 25) performed strenuous exercise on a bicycle ergometer. Blood was drawn at baseline, immediately after exercise and 2 h later. Platelet aggregation was measured with Multiplate® Analyzer. Thrombin
-
Platelet factor 4 promotes deep venous thrombosis by regulating the formation of neutrophil extracellular traps Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Wenqiang Li, Decai Chi, Shuai Ju, Xinyi Zhao, Xiaoyan Li, Junjie Zhao, Huiqi Xie, Yao Li, Jiaqi Jin, Ge Mang, Zhihui Dong
The presence of neutrophil extracellular traps (NETs) in thrombotic diseases has been extensively studied. The exact mechanism of NET formation in deep venous thrombosis (DVT) has not been largely studied. This study is aimed to explore the role of NETs and their interaction with platelet factor 4 (PF4) in DVT. In plasma samples from 51 healthy volunteers and 52 DVT patients, NET markers and PF4 were
-
Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Yvonne K. Jongejan, Noa A. Linthorst, Elisa Schrader Echeverri, Sebastiaan N.J. Laan, Richard J. Dirven, James E. Dahlman, Bart J.M. van Vlijmen, Cécile V. Denis, Jeroen C.J. Eikenboom
Von Willebrand factor (VWF) plays a pathophysiological role in hemostatic disorders. Partial inhibition of the gene through small interfering RNA (siRNA)-mediated allele-selective silencing could be a promising therapeutic strategy. For von Willebrand disease, allele-selectively inhibiting dominant-negative -alleles might ameliorate the phenotype. For thrombotic disorders, partial VWF reduction can
-
Fundamental considerations for designing endothelialized in vitro models of thrombosis Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Titus P. Lemmens, Vanessa Bröker, Minke Rijpkema, Christopher C.W. Hughes, Leon J. Schurgers, Judith M.E.M. Cosemans
Endothelialized models for cardiovascular disease have contributed greatly to our current understanding of the complex molecular mechanisms underlying thrombosis. To further elucidate these mechanisms, it is important to consider which fundamental aspects to incorporate into an model. In this review, we will focus on the design of in vitro endothelialized models of thrombosis. Expanding our understanding
-
Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study Thromb. Res. (IF 7.5) Pub Date : 2024-03-05 Oğuzhan Firat, Emre Kara, Ümit Yavuz Malkan, Kutay Demirkan, Ahmet Çağkan Inkaya
Tigecycline-associated hypofibrinogenemia has been reported as an important adverse effect in recent years, but controlled studies minimizing confounding factors are needed. The objective of our study was to assess changes in fibrinogen levels in patients for hospitalization, comparing two antibiotic episodes (tigecycline and other) within the same patients. The retrospective, self-controlled case
-
Effects of gender affirming hormone therapy with testosterone on coagulation and hematological parameters in transgender people assigned female at birth: A systematic review and meta-analysis Thromb. Res. (IF 7.5) Pub Date : 2024-03-04 Daniele Tienforti, Daniele Pastori, Arcangelo Barbonetti
Hormone replacement therapy is associated with an increased thromboembolic risk. The effects of testosterone (T) on coagulation markers in people assigned female at birth (AFAB) under gender affirming hormone therapy (GAHT) are not well described. Systematic review and meta-analysis on English-language articles retrieved from PubMed, Scopus and Cochrane Library up to April 2023 investigating T therapy
-
Impact of very low dose rivaroxaban in addition to dual antiplatelet therapy on endogenous fibrinolysis in acute coronary syndrome: The VaLiDate-R study Thromb. Res. (IF 7.5) Pub Date : 2024-03-03 Ying X. Gue, Vassilios Memtsas, Rahim Kanji, David M. Wellsted, Amanda Busby, Megan Smith, Enric Vilar, Alisdair Ryding, Deepa J. Arachchillage, Diana A. Gorog
Impaired endogenous fibrinolysis is adverse cardiovascular risk factor in acute coronary syndrome (ACS) patients. Addition of very low dose rivaroxaban (VLDR) to dual antiplatelet therapy (DAPT) reduces cardiovascular events but increases bleeding. We aimed to assess whether addition of VLDR to DAPT can enhance endogenous fibrinolysis. In a prospective, open-label trial, we assessed endogenous fibrinolysis
-
Effect of statin intake on FVIII levels and bleeding outcomes in hypercholesterolemic patients with hemophilia A Thromb. Res. (IF 7.5) Pub Date : 2024-03-02 Francesco Paciullo, Stefania Momi, Maria Elisa Mancuso, Cristina Santoro, Mariasanta Napolitano, Giancarlo Castaman, Ezio Zanon, Laura Contino, Raimondo De Cristofaro, Rita Carlotta Santoro, Paolo Gresele
-
Anticoagulation with argatroban using hemoclot™ targets is safe and effective in CARDS patients receiving venovenous extracorporeal membrane oxygenation: An exploratory bi-centric cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-03-02 Timo Mayerhöfer, Michael Joannidis, Andreas Peer, Fabian Perschinka, Dietmar Fries, Peter Mair, Lukas Gasteiger, Mirjam Bachler, Juliane Kilo, Harald Herkner, Michael Schwameis, Peter Schellongowski, Bernhard Nagler, Andrea Kornfehl, Thomas Staudinger, Nina Buchtele
Direct thrombin inhibitors, including argatroban, are increasingly used for anticoagulation during venovenous extracorporeal membrane oxygenation (VV ECMO). In many centers activated partial thromboplastin time (aPTT) is used for monitoring, but it can be affected by several confounders. The aim of this study was to evaluate the safety and efficacy of anticoagulation with argatroban titrated according
-
Fragility and long-term clinical outcomes in patients with venous thromboembolism receiving direct oral anticoagulants: From the COMMAND VTE REGISTRY-2 Thromb. Res. (IF 7.5) Pub Date : 2024-02-29 Yoshito Ogihara, Yugo Yamashita, Takeshi Morimoto, Ryuki Chatani, Kazuhisa Kaneda, Yuji Nishimoto, Nobutaka Ikeda, Yohei Kobayashi, Satoshi Ikeda, Kitae Kim, Moriaki Inoko, Toru Takase, Shuhei Tsuji, Maki Oi, Takuma Takada, Kazunori Otsui, Jiro Sakamoto, Takeshi Inoue, Shunsuke Usami, Po-Min Chen, Kiyonori Togi, Norimichi Koitabashi, Seiichi Hiramori, Kosuke Doi, Hiroshi Mabuchi, Yoshiaki Tsuyuki,
There is limited data on the safety of direct oral anticoagulants (DOACs) in fragile patients with venous thromboembolism (VTE). We used the COMMAND VTE Registry-2 enrolling patients with acute symptomatic VTE. The study population consisted of 3928 patients receiving DOACs, who were divided into fragile (2136 patients) and non-fragile groups (1792 patients). Fragility was defined as patients of age ≥ 75 years
-
Comparison of inferior vena cava filter use and outcomes between cancer and non-cancer patients in a tertiary hospital Thromb. Res. (IF 7.5) Pub Date : 2024-02-28 Néstor López, Carles Zamora-Martinez, Marc Montoya-Rodes, Cristina Gabara, María Ortiz, Jesús Aibar
While accepted indications for the use of inferior vena cava filter (IVCF) in patients with a venous thromboembolism (VTE) have remained stable, their use continues to be frequent. Retrieval rates are still low, being particularly notable in the population with cancer. This study aims to review the rate of adherence to guidelines recommendation and to compare retrieval rates and complications in both
-
Complications associated to midline- and long peripheral catheters in adults. Systematic review of literature and proposal for a standardized model for data collection Thromb. Res. (IF 7.5) Pub Date : 2024-02-26 Adam Fabiani, Nicola Aversana, Marilena Santoro, Gianfranco Sanson
Long peripheral catheters (LPCs) and midline catheters (MCs) are indiscriminately labelled with different names, leading to misclassifications both in primary and secondary studies. The available studies used different methods to report the incidence of catheter-related complications, affecting the possibility of properly comparing the catheter outcomes. The aim of this review was to explore the complications
-
Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry Thromb. Res. (IF 7.5) Pub Date : 2024-02-24 Carmine Siniscalchi, Behnood Bikdeli, David Jiménez, José María Suriñach, Pablo Demelo-Rodríguez, Farès Moustafa, Aída Gil-Díaz, Alberto García-Ortega, Hanh My Bui, Manuel Monreal, RIETE Investigators
The association between statin use and mortality in patients with deep vein thrombosis (DVT) has not been rigorously evaluated. We used the data in the RIETE registry to examine the association between statin use and mortality at 3 months. We used mixed effects survival models accounting for clinical covariates and clustering of patients in enrolling centers. From January 2009 through April 2022, there
-
Considerations for instituting pediatric pulmonary embolism response teams: A tool kit Thromb. Res. (IF 7.5) Pub Date : 2024-02-22 Madhvi Rajpurkar, Rachel P. Rosovsky, Suzan Williams, Anthony K.C. Chan, C. Heleen van Ommen, E. Vincent S. Faustino, Melissa White, Mihir Parikh, Nongnuch Sirachainan, Tina Biss, Neil A. Goldenberg
The incidence of pediatric pulmonary embolism (PE) has increased by 200 % in the last decade, but at a single center, it is still infrequent. Given the unique epidemiologic features of pediatric PE, diagnosis is often delayed, and the management is empiric, based on individual physician experience or preference. Thus, there is a strong need for center-specific uniform management of pediatric PE patients
-
Patterns of atrial fibrillation anticoagulation with rivaroxaban — 7-year follow-up from the Dresden NOAC registry Thromb. Res. (IF 7.5) Pub Date : 2024-02-19 Luise Tittl, Sandra Marten, Christiane Naue, Jan Beyer-Westendorf
Data on long-term effectiveness and safety of rivaroxaban for stroke prevention in atrial fibrillation (SPAF) are scarce and not available from randomized clinical trials. We used data from the prospective, non-interventional to evaluate rates of stroke/transient ischaemic attack (TIA)/systemic embolism (SE) and ISTH major bleeding, in general and changes of event patterns over time. Between 1st October
-
Diagnostic strategies in postpartum individuals with suspected venous thromboembolism: A scoping review Thromb. Res. (IF 7.5) Pub Date : 2024-02-19 Gurjeet Bhangu, Alistair Murray, Areeb Qayyum, Natasha Goumeniouk, Steve Goodacre, Beverley J. Hunt, Omar Touhami, Jodie Tester, Megan Rees, Gary Hammerschlag, Diane Pascoe, Paul E. Ronksley, James A. King, Hyun Choi, Shaunagh McDermott, Gregoire Le Gal, Leslie Skeith
The risk of venous thromboembolism (VTE) is increased postpartum and contributes to important morbidity and mortality. While there have been advances in evaluating diagnostic algorithms for suspected VTE during pregnancy, there is limited data for postpartum individuals. We conducted a scoping review to describe and evaluate diagnostic strategies used to investigate suspected VTE in postpartum individuals
-
DOACs: A perfect fit for patients with bariatric surgery? Thromb. Res. (IF 7.5) Pub Date : 2024-02-18 Nicolas Gendron, Azita H. Talasaz
-
The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-02-17 Yongkang Zhang, Qingzhi Ran, Kangli Yin, Yinkai Wang, Jiarui Liu, Yuan Zong, Yuzhen Wang, Yemin Cao
Peripheral arterial disease (PAD) affects approximately 236 million people worldwide. Therefore, this study aimed to investigate the relationship between genotype polymorphisms and clopidogrel resistance (CR) following revascularization in patients with PAD. In total, 345 patients who underwent PAD revascularization were monitored for five years and risk factors for ischemic events were identified
-
Standardized direct oral anticoagulants prescription for treatment of acute venous thromboembolism in the emergency department: A quality improvement initiative Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 C. Simard, L. Poirier-Blanchette, A. Rizzolo, T. Cafaro, R. Kerzner, H. Mantzanis, M. Koolian
-
Multitarget strategy of GATA3 and high-grade serous ovarian carcinoma: Where are we now? Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Mohnad Abdalla, Amr Ahmed El-Arabey, Zhongtao Gai
-
Pregnancy outcomes in Chinese women with mechanical heart valves receiving warfarin treatment throughout pregnancy: 14-year experience Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Tianyu Li, Lei Chen, Mei Peng, Guobao Song, Chunyan Wang, Qiyun Peng, Shenglan Tan
The purpose was to evaluate pregnancy outcomes and risk factors associated with fetal complications in Chinese pregnant women with mechanical heart valves (MHVs) taking low-dose warfarin, aiming to fill in the research gap of this area. Between June 2010 and Aug 2023, 122 patients with MHVs who had 151 pregnancies and received warfarin throughout pregnancy were included. We compared them with 302 paired
-
Altered fibrin clot properties are associated with the progression of chronic kidney disease in atrial fibrillation Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Zbigniew Heleniak, Paweł T. Matusik, Anetta Undas
Formation of denser and resistant to lysis fibrin clot networks has been shown in chronic kidney disease (CKD) and atrial fibrillation (AF). We investigated whether such prothrombotic fibrin clot properties are associated with faster progression of CKD in AF patients. We recruited 265 AF patients (men 49.1 %, median age of 64.0 years, median estimated glomerular filtration rate [eGFR] of 77.0 ml/min/1
-
The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia Thromb. Res. (IF 7.5) Pub Date : 2024-02-16 Giovangiacinto Paterno, Raffaele Palmieri, Cristiano Tesei, Andrea Nunzi, Giorgia Ranucci, Flavia Mallegni, Federico Moretti, Elisa Meddi, Ilaria Tiravanti, Massimiliano Marinoni, Camilla Page, Solaria Fagiolo, Elisa Buzzatti, Roberto Secchi, Carmelo Gurnari, Luca Maurillo, Francesco Buccisano, Adriano Venditti, Maria Ilaria Del Principe
Coagulation disorders frequently complicate the clinical course of acute myeloid leukemia (AML) patients. This study examined the frequency and prognostic significance, with regards of early mortality, of the presence of overt disseminated intravascular coagulation (DIC) at AML diagnosis and its correlation with clinical and biological characteristics.
-
Current and potentially novel antithrombotic treatment in acute ischemic stroke Thromb. Res. (IF 7.5) Pub Date : 2024-02-15 Angelique Ceulemans, Henri M.H. Spronk, Hugo ten Cate, Wim H. van Zwam, Robert J. van Oostenbrugge, Magdolna Nagy
Acute ischemic stroke (AIS) is the most common type of stroke and requires immediate reperfusion. Current acute reperfusion therapies comprise the administration of intravenous thrombolysis and/or endovascular thrombectomy. Although these acute reperfusion therapies are increasingly successful, optimized secondary antithrombotic treatment remains warranted, specifically to reduce the risk of major
-
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-02-15 Li Bao, Li-juan Fang, Meng-yu Xiao, Min-qiu Lu, Bin Chu, Lei Shi, Shan Gao, Qiu-qing Xiang, Yu-tong Wang, Xi Liu, Yue-hua Ding, Yuan Chen, Meng-zhen Wang, Wei-kai Hu, Cheng-yu Guo, Ling-yun Chen, Kai Sun
Multiple myeloma (MM) significantly increases the risk of venous thromboembolism (VTE) within 6 months of treatment initiation. The IMPEDE VTE score is a VTE risk prediction model which is recently incorporated into the National Comprehensive Cancer Network (NCCN) guidelines, but it lacks validation among Asians, including Chinese MM patients. We performed a retrospective chart review of 405 Chinese
-
Letter in response to a recent article by Zhang et al.[1] Thromb. Res. (IF 7.5) Pub Date : 2024-02-15 Martina Perego, Maria Calloni, Alba Taino, Chiara Cogliati, Antonio Gidaro
-
Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort study Thromb. Res. (IF 7.5) Pub Date : 2024-02-13 Renate C.A.E. van Uden, Tessa C.C. Jaspers, Karina Meijer, Karlijn J. van Stralen, Barbara Maat, Nakisa Khorsand, Hein A.W. van Onzenoort, Eleonora L. Swart, Harmen J. Huls, Ron A.A. Mathôt, Michaël V. Lukens, Patricia M.L.A. van den Bemt, Matthijs L. Becker
Guidelines advise 50 % and 25 % dose reduction of the therapeutic nadroparin dose (86 IU/kg) in patients with eGFR 15–29 and 30-60 ml/min respectively. For monitoring, peak anti-Xa levels are suggested. Data lack whether this results in therapeutic anti-Xa levels or in anti-Xa levels that are comparable to those of patients without renal impairment. To determine dose ranges in patients with renal impairment
-
Anticoagulation of pediatric patients with venous thromboembolism in 2023 Thromb. Res. (IF 7.5) Pub Date : 2024-02-10 C. Heleen van Ommen, Saskia E. Luijnenburg
-
Recapitulating the immune system of hemophilia A patients with inhibitors using immunodeficient mice Thromb. Res. (IF 7.5) Pub Date : 2024-02-08 Sheng-Chieh Chou, Ching-Tzu Yen, Yung-Li Yang, Shu-Huey Chen, Jiaan-Der Wang, Meng-Ni Fan, Li-Fu Chen, I-Shing Yu, Dong-Yan Tsai, Kuo-I Lin, Mi-Hua Tao, Jui-ching Wu, Shu-Wha Lin
Treating hemophilia A patients who develop inhibitors remains a clinical challenge. A mouse model of hemophilia A can be used to test the efficacy of strategies for inhibitor suppression, but the differences in the immune systems of mice and humans limit its utility. To address this shortcoming, we established a humanized NOD/SCID-IL2rγ hemophilia A (hu-NSG-HA) mouse model with a severely deficient
-
White blood cell subtypes and neutrophil extracellular traps as biomarkers for stroke etiology Thromb. Res. (IF 7.5) Pub Date : 2024-02-06 Kousar Ahmadi, Ehsan Alimohammadi
-
Frequency of the p.Thr241Asn mutation in Chinese patients with congenital factor VII deficiency Thromb. Res. (IF 7.5) Pub Date : 2024-02-06 Puhui Zhou, Yan Peng, Qingcheng Li, Qingshui Huang, Yunyuan Kong
-
Translating mechanisms into therapeutic strategies for immune thrombocytopenia (ITP): Lessons from clinical trials Thromb. Res. (IF 7.5) Pub Date : 2024-02-06 Mahda Delshad, Zeinab Davoodi-Moghaddam, Atieh Pourbagheri-Sigaroodi, Mohammad Faranoush, Hassan Abolghasemi, Davood Bashash
Immune thrombocytopenia (ITP) is an autoimmune disorder that causes a significant reduction in peripheral blood platelet count. Fortunately, due to an increased understanding of ITP, there have been significant improvements in the diagnosis and treatment of these patients. Over the past decade, there have been a variety of proven therapeutic options available for ITP patients, including intravenous
-
A noncanonical splicing variant c.875-5 T > G in von Willebrand factor causes in-frame exon skipping and type 2A von Willebrand disease Thromb. Res. (IF 7.5) Pub Date : 2024-02-05 Qian Liang, Ziqi Zhang, Biying Ding, Yanyan Shao, Qiulan Ding, Jing Dai, Xiaobo Hu, Wenman Wu, Xuefeng Wang
-
Thrombin as target for prevention of recurrent events after acute coronary syndromes Thromb. Res. (IF 7.5) Pub Date : 2024-02-05 M. Cecilia Bahit, C. Michael Gibson
The mechanism underlying thrombus formation in acute coronary syndrome (ACS) involves both platelets and thrombin. While both pathways are targeted in acute care, platelet inhibition has been predominantly administered in the chronic phase, yet thrombin plays a key role in platelet activation and fibrin formation. Among ACS patients, there is also a persistent chronic increase in thrombin generation
-
AAV mediated gene therapy for haemophilia B: From the early attempts to modern trials Thromb. Res. (IF 7.5) Pub Date : 2024-02-04 Vincent Muczynski, Amit C. Nathwani
Early gene therapy clinical trials for the treatment of Haemophilia B have been instrumental to our global understanding of gene therapy and have significantly contributed to the rapid expansion of the field. The use of adeno-associated viruses (AAVs) as vectors for gene transfer has successfully led to therapeutic expression of coagulation factor IX (FIX) in severe haemophilia B patients. Expression
-
Extended-duration thromboprophylaxis following major abdominopelvic surgery – For everyone or selected cases only? Thromb. Res. (IF 7.5) Pub Date : 2024-02-04 A. Noureldin, V. Ivankovic, M. Delisle, T.F. Wang, R.C. Auer, M. Carrier
Major abdominopelvic surgery is an important risk factor for postoperative venous thromboembolism (VTE). VTE is the leading cause of 30-day postoperative mortality in patients with cancer undergoing major abdominopelvic surgery. Randomized controlled trials have shown that extended duration thromboprophylaxis using a low molecular weight heparin or a direct oral anticoagulant significantly decreases
-
Levels of procoagulant factors and peak thrombin generation in relation to dementia risk in older adults: The Cardiovascular Health Study Thromb. Res. (IF 7.5) Pub Date : 2024-02-04 Laura B. Harrington, Alexa N. Ehlert, Evan L. Thacker, Nancy S. Jenny, Oscar Lopez, Mary Cushman, Nels C. Olson, Annette Fitzpatrick, Kenneth J. Mukamal, Majken K. Jensen
Markers of hemostasis such as procoagulant factors and peak thrombin generation are associated with cardiovascular outcomes, but their associations with dementia risk are unclear. We aimed to evaluate prospective associations of selected procoagulant factors and peak thrombin generation with dementia risk. We measured levels of 7 hemostatic factors (fibrinogen, factor VII coagulant activity [FVIIc]
-
VTE risk assessment, prevention and diagnosis in pregnancy Thromb. Res. (IF 7.5) Pub Date : 2024-02-03 Ahmed Lutfi, Ellen O'Rourke, Maeve Crowley, Eilidh Craig, Amy Worrall, Barry Kevane, Fergal O'Shaughnessy, Jennifer Donnelly, Brian Cleary, Fionnuala Ní Áinle
Venous thromboembolism (VTE) is still reported as the leading cause of direct maternal death in pregnancy in serial international reports in developed countries. VTE risk is higher during pregnancy but is further increased by additional well-characterized risk factors. International guidelines recommend that formal VTE risk assessment should be conducted at least in early pregnancy, at delivery and
-
The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study Thromb. Res. (IF 7.5) Pub Date : 2024-02-02 Daisuke Sueta, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Makoto Mo, Takeshi Kimura, Kenichi Tsujita
The multicenter, open-label, randomized clinical trial ONCO DVT compared 3-month and 12-month edoxaban treatment regimens for isolated distal deep vein thrombosis (DVT) and suggested potential benefits of prolonged edoxaban treatment in terms of thrombotic risk. However, the risk-benefit balance of prolonged edoxaban treatment in patients with renal function remains unclear. To compare the safety and
-
Disordered gut microbiota and alterations in the serum metabolome are associated with venous thromboembolism Thromb. Res. (IF 7.5) Pub Date : 2024-01-28 Zeqin Fan, Shuanglan Xu, Yishu Deng, Li Wei, Jiao Yang, Xiqian Xing
Introduction The gut microbiome plays a crucial role in various diseases, and its regulation is a potential treatment option for these conditions. However, the relationship between the gut microbiome and venous thromboembolism (VTE) remains poorly explored. Methods In this study, we collected feces and serum samples from 8 VTE patients and 7 healthy controls. The gut microbiota and serum metabolites
-
The search for the underlying mutations causing VWD in 13 Venezuelan families Thromb. Res. (IF 7.5) Pub Date : 2024-02-01 Rita Marchi, Tobias Obser, Florian Oyen, Arlette Ruiz-Sáez, Apsara Boadas, Marion Echenagucia, Sonja Schneppenheim, Ulrich Budde, Reinhard Schneppenheim
Abstract not available
-
Incidence and risk factors of post-thrombotic syndrome in patients with isolated calf vein thrombosis. Findings from the GARFIELD-VTE registry Thromb. Res. (IF 7.5) Pub Date : 2024-02-01 Paolo Prandoni, Sylvia Haas, Meg Fluharty, Sebastian Schellong, Shinya Goto, Peter MacCallum, Eric Tse, Karen Pieper, Gloria Kayani, Ajay Kakkar
Abstract not available
-
-
Activated protein C and free protein S in patients with mild to moderate bleeding disorders Thromb. Res. (IF 7.5) Pub Date : 2024-01-26 Dino Mehic, Theresa Schramm, Birgit Forstner-Bergauer, Helmuth Haslacher, Cihan Ay, Ingrid Pabinger, Johanna Gebhart
-
Outpatient management of cancer-associated pulmonary embolism: A post-hoc analysis from the HOME-PE trial Thromb. Res. (IF 7.5) Pub Date : 2024-01-26 Sérine Chaibi, Pierre-Marie Roy, Armelle Arnoux Guénégou, Yohann Tran, Olivier Hugli, Andréa Penaloza, Francis Couturaud, Cécile Tromeur, Tali-Anne Szwebel, Gilles Pernod, Antoine Elias, Alexandre Ghuysen, Ygal Benhamou, Nicolas Falvo, Henry Juchet, Mathilde Nijkeuter, Ronne Mairuhu, Laura M. Faber, Isabelle Mahé, Karine Montaclair, Olivier Sanchez
Introduction Cancer-related pulmonary embolism (PE) is associated with poor prognosis. Some decision rules identifying patients eligible for home treatment categorize cancer patients at high risk of complications, precluding home treatment. We sought to assess the effectiveness and the safety of outpatient management of patients with low-risk cancer-associated PE. Methods In the HOME-PE trial, hemodynamically
-
Risk of thromboembolism according to statin treatment in patients with cancer: A nationwide nested case-control study Thromb. Res. (IF 7.5) Pub Date : 2024-01-25 Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
-
A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban Thromb. Res. (IF 7.5) Pub Date : 2024-01-24 Karl Mangion, Kevin Vella, Alex Gatt, Amy Marie Vella, Marica Borg, Denise Borg-Aquilina, Jonathan Douxfils, Liberato Camilleri, Nicoletta Riva
-
Anticoagulation in cancer patients with atrial fibrillation and grade 3–4 thrombocytopenia Thromb. Res. (IF 7.5) Pub Date : 2024-01-23 Genady Drozdinsky, Noam Arad, Galia Spectre, Nir Livneh, Itamar Poran, Pia Raanani, Anna Falanga, Hugo ten Cate, Anat Gafter-Gvili, Avi Leader
Introduction Atrial fibrillation or flutter (AF) is prevalent in cancer patients. Many of these patients have an indication for anticoagulation (AC) but are also at risk for developing chemotherapy-induced thrombocytopenia. There are scarce data regarding management of AC and risk of bleeding and thrombosis in cancer patients with AF and thrombocytopenia. Aim To assess anticoagulation management and
-
Late venous thromboembolism in survivors of adolescent and young adult cancer: A population-based study in California Thromb. Res. (IF 7.5) Pub Date : 2024-01-15 Renata Abrahão, Ann Brunson, Jessica Chubak, Karen J. Wernli, Hazel B. Nichols, Chun Chao, Kathryn J. Ruddy, Erin E. Hahn, Qian Li, Marcio H. Malogolowkin, Candice A.M. Sauder, Lawrence H. Kushi, Ted Wun, Theresa H.M. Keegan
Introduction Venous thromboembolism (VTE), a common complication in cancer patients, occurs more often during the initial phase of treatment. However, information on VTE beyond the first two years after diagnosis (‘late VTE’) is scarce, particularly in young survivors. Methods We examined the risk of, and factors associated with, late VTE among adolescents and young adults (AYA, 15–39 years) diagnosed
-
Analysis of NETs (neutrophil extracellular traps) in coronary thrombus and peripheral blood of patients with ST-segment elevation myocardial infarction Thromb. Res. (IF 7.5) Pub Date : 2024-01-20 Ana Blasco, Axel Rosell, Raquel Castejón, María José Coronado, Ana Royuela, Elvira Ramil, Silvia Elorza, Charlotte Thålin, Paloma Martín, Basilio Angulo, Beatriz Rascón, Sergio García-Gómez, Inuntze Zabala, Javier Ortega, Lorenzo Silva, Carmen Bellas
Abstract not available
-
External validation of the PE-SARD risk score for predicting early bleeding in acute pulmonary embolism in the RIETE Registry Thromb. Res. (IF 7.5) Pub Date : 2024-01-20 Romain Chopard, Laurent Bertoletti, Gregory Piazza, David Jimenez, Giovanni Barillari, Pilar Llamas, Carmen Mª. Rubio, Avinash Aujayeb, Manuel Monreal, Nicolas Meneveau
Introduction The PE-SARD score (syncope, anemia, renal dysfunction) was developed to predict the risk of major bleeding in the acute phase of pulmonary embolism (PE). Methods We analyzed data from 50,686 patients with acute PE included in the RIETE registry to externally validate the PE-SARD score. We calculated the overall reliability of the PE-SARD score, as well as discrimination and calibration
-
TRanEXamic acid to decrease Heavy Menstrual Bleeding in individuals anticoagulated for venous thromboembolism (T-REX HMB): Health care practitioner survey Thromb. Res. (IF 7.5) Pub Date : 2024-01-17 Jameel Abdulrehman, Amye Harrigan, Camille Simard, Vicky Tagalakis, Sudeep Shivakumar
Abstract not available